We therefore tested three prostate cancer cell lines with different PTEN status: 22RV1 (PTEN+/+), DU145 (PTEN+/-), and PC3 (PTEN-/-) for the drug sensitivity to BETi. This evidence concerns the gene PTEN and prostate carcinoma.